Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pharmacologic activation of G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma

ABSTRACT: We examine the effect of GPER activation on murine pancreatic ductal adenocarcinoma cell lines

ORGANISM(S): Mus musculus

PROVIDER: GSE117312 | GEO | 2018/10/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Pharmacologic activation of G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma

Project description:Pharmacologic activation of G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma

| PRJNA481745 | ENA

Pharmacologic Activation of the G Protein-Coupled Estrogen Receptor Inhibits Pancreatic Ductal Adenocarcinoma.

Project description:Background & aimsFemale sex is associated with lower incidence and improved clinical outcomes for most cancer types including pancreatic ductal adenocarcinoma (PDAC). The mechanistic basis for this sex difference is unknown. We hypothesized that estrogen signaling may be responsible, despite the fact that PDAC lacks classic nuclear estrogen receptors.MethodsHere we used murine syngeneic tumor models and human xenografts to determine that signaling through the nonclassic estrogen receptor G protein-coupled estrogen receptor (GPER) on tumor cells inhibits PDAC.ResultsActivation of GPER with the specific, small molecule, synthetic agonist G-1 inhibited PDAC proliferation, depleted c-Myc and programmed death ligand 1 (PD-L1), and increased tumor cell immunogenicity. Systemically administered G-1 was well-tolerated in PDAC bearing mice, induced tumor regression, significantly prolonged survival, and markedly increased the efficacy of PD-1 targeted immune therapy. We detected GPER protein in a majority of spontaneous human PDAC tumors, independent of tumor stage.ConclusionsThese data, coupled with the wide tissue distribution of GPER and our previous work showing that G-1 inhibits melanoma, suggest that GPER agonists may be useful against a range of cancers that are not classically considered sex hormone responsive and that arise in tissues outside of the reproductive system.

| S-EPMC7578406 | biostudies-literature

Pancreatic ductal adenocarcinoma

Project description:Pancreatic ductal adenocarcinoma

| PRJNA432344 | ENA

Gene expression in pancreatic ductal adenocarcinoma

Project description:To further develop our understanding of the gene expression signature of pancreatic ductal adenocarcinoma Gene expression signatures in macrodissected resected pancreatic ductal adenocarcinoma specimens

2014-03-14 | E-GEOD-55643 | biostudies-arrayexpress

Pancreatic ductal adenocarcinoma

Project description:We sought to determine whether certain miRNAs could serve as a biomarker for the prognosis of pancreatic ductal adenocarcinoma (PDAC) and uncover the uncharacterized miRNAs function in the pancreatic carcinogenesis

2019-10-01 | GSE109918 | GEO

MS-based proteomic analysis of pancreatic ductal adenocarcinoma

Project description:Disease-related quantitative protein expressions of pancreatic ductal adenocarcinoma were acquired by high accuracy mass spectrometry following liquid chromatography peptide separation.

2022-03-21 | PXD032681 | JPOST Repository

Expression profiling of pancreatic adenocarcinoma and ductal adenocarcinoma cell lines.

Project description:We characterized baseline gene expression profiles for eleven human pancreatic adenocarcinoma and ductal adenocarcinoma cell lines.

2018-11-22 | GSE122818 | GEO

Gene expression in pancreatic ductal adenocarcinoma

Project description:To further develop our understanding of the gene expression signature of pancreatic ductal adenocarcinoma

2014-03-14 | GSE55643 | GEO

Development of lncRNA and Mrna expression signatures for pancreatic ductal adenocarcinoma

Project description:To further development of our lncRNA and mRNA expression approach to pancreatic ductal adenocarcinoma(PDAC), we have employed lncRNA and mRNA microarray expression profiling as a discovery platform to identify lncRNA and mRNA expression in pancreatic ductal adenocarcinoma.Human pancreatic ductal adenocarcinoma tissues and normal pancreatic tissues from PDAC donors and other duodenum diseases donors. analyze mRNA and lncRNA expression in pancreatic ductal adenocarcinoma (PDAC) by microarray platform

2014-11-18 | E-GEOD-57144 | biostudies-arrayexpress

MicroRNA expression in Pancreatic Ductal Adenocarcinoma

Project description:MicroRNA expression in Pancreatic Ductal Adenocarcinoma

| PRJNA588774 | ENA